Oral presentation of column hoc assay of PROMISE 2 abstracts implies that convalescent to 4 or beneath account cephalalgia canicule might be a assay that is advantageous for bodies with abiding migraine
Poster presentation of basic assay from PROMISE 2 showed VYEPTI was associated with greater declines in cephalalgia abundance and canicule of astute cephalalgia medication use vs. placebo in bodies dually diagnosed with abiding cephalalgia and medication overuse headache
Poster presentation of column hoc assay of RELIEF abstraction suggests VYEPTI showed greater astute cephalalgia medication access and decreased headache-related appulse compared to placebo
A affiche presentation will outline the abstraction architecture of ALLEVIATE (trial-in-progress), the aboriginal abstraction to appraise the adeptness and assurance of VYEPTI in patients with anecdotal arrangement headache
DEERFIELD, Ill., April 02, 2022–(BUSINESS WIRE)–Lundbeck today appear new abstracts from an clear abstruse for VYEPTI® (eptinezumab-jjmr), forth with three affiche presentations, are actuality presented at the 2022 Annual Scientific Meeting of the American Academy of Neurology (AAN), which is actuality captivated in being from April 2-7 and around from April 24-26. The allegation are allotment of a column hoc assay of one of two cardinal trials, PROMISE 2 (NCT02974153), a randomized, double-blind abstraction that evaluated VYEPTI for the antitoxin assay of abiding migraine. After-effects showed that a college allotment of bodies with abiding cephalalgia who accomplished a abridgement to 4 or beneath account cephalalgia canicule (MHDs) accomplished bigger bloom outcomes (headache crime as abstinent by the 6-item Cephalalgia Appulse Test (HIT-6) and improvements in Accommodating All-around Impression of Change (PGIC)) and adapted beneath astute medication against bodies with abiding cephalalgia who accomplished college MHDs (5-9, 10-14, ≥15).1 Abstraction participants accustomed VYEPTI 100 mg, 300 mg, or placebo; all assay accoutrements were affiliated for the analysis.
“While Accepted assay goals for bodies with abiding cephalalgia focus on responder ante such as a abridgement in account cephalalgia days, assessing the cardinal of account cephalalgia canicule might be a added aboveboard way to simply accept and acquaint assay objectives to figures alive with migraine,” stated Roger Cady, M.D., Vice President for the National Cephalalgia Foundation, and something for the advance abstraction writers. “Based with this assay from PROMISE 2, adjusting to a assay aspiration connected with larger cephalalgia love and abridgement of astute medicine usage provides an befalling to simply accept additional allusive agency to clear how we reach larger results in migraine.”